Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Cosmo Pharmaceuticals N.V. (CMOPF)
Dublin, IE
Cosmo Pharmaceuticals N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss. It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company was founded in 1997 and is headquartered in Dublin, Ireland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.19% | -5.13% | -8.26% | -33.24% | +22.44% | -24.70% | +55.58% | +79.63% | +2.45% | -37.67% | -37.67% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Medical - Pharmaceuticals: +7.8%-60.7% Q4'25: +6.9% (vs Q4'23)
-
EPS growth Medical - Pharmaceuticals: +20.2%-102.8% Q4'25: +75.0% (vs Q4'23)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-8.7% Q4'25: -27.1% (vs Q4'23)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-10.0% Q4'25: -8.2% (vs Q4'23)
-
ROIC Medical - Pharmaceuticals: +6.1%-2.8% Q4'25: -4.7% (vs Q4'23)
-
Share dilution Medical - Pharmaceuticals: +0.0%-2.7% ★ Q4'25: -0.6% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×1.81× ★ Q4'25: 0.49× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 6 Rev. Ana. 1 EPS Ana. |
Dec 2027 5 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 2 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
60.61M
est: 65.43M (-7.4%)
|
67.66M
est: 71.41M (-5.2%)
|
67.24M
est: 77.15M (-12.8%)
|
65.62M
est: 78.96M (-16.9%)
|
62.50M
est: 50.29M (+24.3%)
|
60.95M
est: 66.44M (-8.3%)
|
65.07M
est: 70.50M (-7.7%)
|
102.09M
est: 107.85M (-5.3%)
|
92.78M
est: 152.29M (-39.1%)
|
266.79M
est: 266.74M (+0.0%)
|
104.82M
est: 102.19M (+2.6%)
|
118.07M
103.13M – 177.66M
+15.5% YoY
|
136.67M
94.74M – 245.68M
+15.8% YoY
|
195.13M
149.82M – 327.11M
+42.8% YoY
|
279.31M
214.46M – 468.24M
+43.1% YoY
|
410.13M
314.90M – 687.54M
+46.8% YoY
|
| EBITDA |
262.97M
est: 22.16M (+1,086.5%)
|
28.44M
est: 24.19M (+17.6%)
|
-28.81M
est: 26.13M (-210.3%)
|
-12.33M
est: 26.74M (-146.1%)
|
-7.02M
est: 17.03M (-141.2%)
|
7.84M
est: 22.50M (-65.2%)
|
17.81M
est: 23.88M (-25.4%)
|
46.74M
est: 36.53M (+28.0%)
|
19.70M
est: 51.59M (-61.8%)
|
165.71M
est: 84.69M (+95.7%)
|
2.36M
est: 32.44M (-92.7%)
|
37.49M
32.74M – 56.41M
+15.5% YoY
|
43.39M
30.08M – 78.00M
+15.8% YoY
|
61.95M
47.57M – 103.85M
+42.8% YoY
|
88.68M
68.09M – 148.66M
+43.1% YoY
|
130.22M
99.98M – 218.29M
+46.8% YoY
|
| EBIT |
254.48M
est: 15.32M (+1,560.8%)
|
27.61M
est: 16.72M (+65.1%)
|
-32.35M
est: 18.07M (-279.1%)
|
-16.81M
est: 18.49M (-190.9%)
|
-12.78M
est: 11.78M (-208.5%)
|
1.80M
est: 15.56M (-88.4%)
|
11.10M
est: 16.51M (-32.8%)
|
33.63M
est: 25.26M (+33.2%)
|
6.15M
est: 35.66M (-82.8%)
|
153.42M
est: 55.55M (+176.2%)
|
-10.48M
est: 21.28M (-149.2%)
|
24.59M
21.48M – 37.00M
+15.5% YoY
|
28.46M
19.73M – 51.17M
+15.8% YoY
|
40.64M
31.20M – 68.13M
+42.8% YoY
|
58.17M
44.67M – 97.52M
+43.1% YoY
|
85.42M
65.58M – 143.20M
+46.8% YoY
|
| Net Income |
248.19M
est: 279.24M (-11.1%)
|
19.34M
est: 23.10M (-16.3%)
|
-32.45M
est: -37.65M (+13.8%)
|
-18.06M
est: -21.11M (+14.5%)
|
-24.49M
est: -27.59M (+11.2%)
|
-7.90M
est: -5.02M (-57.4%)
|
21.67M
est: 10.32M (+109.9%)
|
17.23M
est: 19.27M (-10.6%)
|
-4.93M
est: 31.29M (-115.8%)
|
133.24M
est: 127.29M (+4.7%)
|
-3.63M
est: -243.7K (-1,389.9%)
|
10.38M
7.24M – 19.50M
+4,358.0% YoY
|
38.31M
26.74M – 71.99M
+269.2% YoY
|
52.30M
36.51M – 98.28M
+36.5% YoY
|
110.44M
77.10M – 207.55M
+111.2% YoY
|
331.28M
231.28M – 622.58M
+200.0% YoY
|
| SGA |
2.28M
est: 3.10M (-26.4%)
|
3.80M
est: 3.38M (+12.4%)
|
15.86M
est: 3.65M (+334.3%)
|
18.24M
est: 3.74M (+388.0%)
|
9.86M
est: 2.38M (+313.9%)
|
4.48M
est: 3.15M (+42.5%)
|
2.81M
est: 3.34M (-15.9%)
|
3.55M
est: 5.11M (-30.5%)
|
5.33M
est: 7.21M (-26.1%)
|
7.41M
est: 22.43M (-66.9%)
|
26.96M
est: 8.59M (+213.8%)
|
9.93M
8.67M – 14.94M
+15.5% YoY
|
11.49M
7.97M – 20.66M
+15.8% YoY
|
16.41M
12.60M – 27.50M
+42.8% YoY
|
23.48M
18.03M – 39.37M
+43.1% YoY
|
34.48M
26.48M – 57.81M
+46.8% YoY
|
| EPS |
17.60
est: 17.01 (+3.5%)
|
1.37
est: 1.41 (-2.6%)
|
-2.19
est: -2.29 (+4.5%)
|
-1.20
est: -1.29 (+6.7%)
|
-1.67
est: -1.68 (+0.6%)
|
-0.55
est: -0.31 (-79.9%)
|
1.29
est: 0.63 (+105.1%)
|
1.05
est: 1.17 (-10.5%)
|
-0.31
est: 1.91 (-116.3%)
|
8.15
est: 7.97 (+2.2%)
|
-0.23
est: -0.02 (-1,407.4%)
|
0.65
0.45 – 1.22
+4,358.0% YoY
|
2.40
1.67 – 4.51
+269.2% YoY
|
3.27
2.29 – 6.15
+36.5% YoY
|
6.92
4.83 – 13.00
+111.2% YoY
|
20.74
14.48 – 38.99
+200.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-18 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Giovanni Di Napoli | Chief Executive Officer & Director | 2M | male |
| Alessandro E. Della Cha | Non Executive Chairman | 474.3K | male |
| Niall Donnelly | Executive Vice President of Corporate Governance, Chief Sustainability Officer & Executive Director | 469.3K | male |
| Mauro Severino Ajani | Founder & Non-Executive Director | 58.3K | male |
| Luigi Longo | Chief Scientific Officer | — | male |
| Federico Sommariva | Chief Legal Counsel | — | male |
| Ngo Dinh Nhan | President of Cosmo Intelligent Medical Devices | — | male |
| Davide Malavasi | Qualified Person & Technical Director | — | male |
| Silvia Miliani | Chief HR Officer | — | female |
| Svetlana Sigalova | Chief Financial Officer | — | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CMOPF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
